Overview
Dr. Ginna Laport, MD is a Hematology / Oncology Specialist, who primarily practices in Stanford, CA. She has been practicing for over 27 years and is board certified by the American Board of Internal Medicine. Dr. Laport completed her residency at Univ Of Chicago Hosps, Internal Medicine. Dr. Laport is fluent in English and is currently seeing new patients. Dr. Laport’s practice accepts Aetna, Blue Cross Blue Shield (BCBS), Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Laport’s office at (650) 723-0822.Medical Specialties and Areas of Expertise
Hematology / Oncology Specialist
Education & Training
Univ Of Chicago Hosps, Internal Medicine (Residency)
University of Chicago Hospitals (Residency)
University of Chicago Hospitals (Internship)
Stanford University School of Medicine,Stanford, Ca, United States (Fellowship)
Other Degree - U of Tx Med Sch At Houston, Houston Tx
Other Degree - University of Texas Medical School, Houston
Board Certifications
American Board of Internal Medicine
Medical Conditions Treated
conditions treated by a Hematology / Oncology Specialist, like Dr. Ginna Laport, may include:
Please contact Dr. Laport's office for more information or to schedule a consultation.
Medical Procedures Performed
procedures performed by a Hematology / Oncology Specialist, like Dr. Ginna Laport, may include:
For detailed information, please contact Dr. Laport's office.
Insurances
Top Insurances
Aetna
Blue Cross Blue Shield (BCBS)
Cigna
UnitedHealthcare
View All Insurances
Locations
Recognitions
Publications
Autologous haemopoietic stem
LANCET ONCOLOGY, 2011
Autologous or reduced
Jourl of clinical oncology, 2014
Autologous haematopoietic cell transplantation for non
BRITISH JOURL OF HAEMATOLOGY, 2013
Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma
JOURL OF CLINICAL ONCOLOGY, 2013
Graft-Versus-Host Disease
JOURL OF CLINICAL ONCOLOGY, 2013
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid
Kate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, 2013
Alterte Donor Hematopoietic Cell Transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Follicular Lymphoma: Prognostic Factors, Conventiol Therapies
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Immunoglobulin Free Light Chain (FLC) and Heavy Chain
Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishn, A., 2011
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning
JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION, 2011
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment
HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2011
Long-term outcomes in patients with high
BONE MARROW TRANSPLANTATION, 2011
Long-term outcomes of high-dose therapy using busulfan, etoposide
ik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., Arai, S.,
Protective conditioning for acute graft-versus-host disease
NEW ENGLAND JOURL OF MEDICINE, 2005
Multiple unrelated clol abnormalities
LEUKEMIA RESEARCH, 2004
Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft
JOURL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000
The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma
SEMIRS IN ONCOLOGY, 1998
Treatment of adult acute lymphoblastic leukemia
SEMIRS IN ONCOLOGY, 1997
Adoptive Immunotherapy with Cytokine
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011
Autologous versus Reduced
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS
Mueller, A. M., Kohrt, H. E., Laport, G. G., Negrin, R. S., Cha, S., W, 2011
Long-term outcomes in patients with high
BONE MARROW TRANSPLANTATION, 2011
Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy
CURRENT OPINION IN ONCOLOGY, 2010
Phase I/II Trial of GN-BVC
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010
Noninvasive Prediction of Graft-Versus
Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., N, 2010
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged
BONE MARROW TRANSPLANTATION, 2010
Total lymphoid irradiation-antithymocyte globulin conditioning
Biology of blood and marrow transplantation, 2014
Autologous or reduced
Journal of clinical oncology, 2014
Prospective cohort study comparing intravenous busulfan to total body irradiation
BLOOD, 2013
Simplified Validated Prognostic Model for Progression
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013
Autologous haematopoietic cell transplantation for non
BRITISH JOURNAL OF HAEMATOLOGY, 2013
Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma
JOURNAL OF CLINICAL ONCOLOGY, 2013
Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013
Graft-Versus-Host Disease
JOURNAL OF CLINICAL ONCOLOGY, 2013
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid
Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Lapo, 2013
TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN
Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnsto, 2013
Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic
Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., John
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma
BLOOD, 2012
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial
BONE MARROW TRANSPLANTATION, 2012
Alternate Donor Hematopoietic Cell Transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Prophylactic rituximab after allogeneic transplantation decreases B
BLOOD, 2012
Tandem Transplantation for Follicular Lymphoma: The Best of Both Worlds?
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Tandem chemo-mobilization followed by high
BONE MARROW TRANSPLANTATION, 2012
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative
BONE MARROW TRANSPLANTATION, 2012
Changing role of stem cell transplantation in follicular lymphoma.
Hematology / the Education Program of the American Society of Hematolo, 2012
Follicular Lymphoma: Prognostic Factors, Conventional Therapies
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Immunoglobulin Free Light Chain (FLC) and Heavy Chain
Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishnan, , 2011
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011
TLI and ATG conditioning with low risk of graft-versus
BLOOD, 2009
Long-term outcomes of high-dose therapy using busulfan, etoposide
Naik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., Arai, S.
Outcomes Following Allogeneic Hematopoietic Cell Transplantation
Kohrt, H., Turnbull, B., Laport, G., Miklos, D., Shizuru, J., Johnston, 2008
Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results
Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., Strober, S., , 2008
Phase I/II Trial of a Novel Gemcitabine
Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos,, 2008
Long-term remission of Philadelphia chromosome
BLOOD, 2008
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008
Autologous versus reduced
Laport, G., Bredeson, C., Tomblyn, M. R., Kahl, B. S., Goodman, S. A.,
Reduced-intensity conditioning follow by allogeneic hematopoietic cell transplantation for adult
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008
Controversies in lymphoma
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008
Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review
LEUKEMIA & LYMPHOMA, 2008
Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy
Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R., 2007
Mantle cell lymphoma in first complete remission
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007
Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin
Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., , 2007
Rituximab infusion two months after nonmyeloablative transplantation maintains B
Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., , 2006
Clinical outcomes following allogeneic hematopoietic cell transplantation
Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., , 2006
Cytokine induced killer
Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Golds, 2006
High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse
Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Shee, 2006
High-dose carmustine, etoposide
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006
The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006
Haploidentical non-myeloablative allogeneic hematopoietic cell transplantation
Lowsky, R., Heydari, K., Sahaf, B., Shizuru, J., Laport, G., Johnston,, 2005
Rhabdomyolysis after concomitant use of cyclosporine
BONE MARROW TRANSPLANTATION, 2005
Protective conditioning for acute graft-versus-host disease
NEW ENGLAND JOURNAL OF MEDICINE, 2005
A phase I trial with extended cohort of gemcitabine
Arai, S., Negrin, R., Blume, K., Johnston, L., Laport, G., Lowsky, R.,, 2005
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell
BLOOD, 2005
CD34, CD49 and CD8 cell doses do not influence engraftment
EXPERIMENTAL HEMATOLOGY, 2005
Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., S, 2004
Multiple unrelated clonal abnormalities
LEUKEMIA RESEARCH, 2004
Non-myeloablative conditioning with total lymphoid irradiation (TLI)
Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., St, 2003
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed
BLOOD, 2003
Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.
Current hematology reports, 2003
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients
BONE MARROW TRANSPLANTATION, 2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001
Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000
A dose escalation study of total body irradiation followed by high-dose etoposide
BONE MARROW TRANSPLANTATION, 2000
Transplantation with low-density autologous PBSC prepared with BDS60 for women with stage II
CYTOTHERAPY, 2000
The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma
SEMINARS IN ONCOLOGY, 1998
High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer
BONE MARROW TRANSPLANTATION, 1998
Treatment of adult acute lymphoblastic leukemia
SEMINARS IN ONCOLOGY, 1997
Frequently Asked Questions
Is Dr. Ginna Laport accepting new patients?
Does Dr. Ginna Laport offer online booking?
Does Dr. Ginna Laport offer telehealth appointments?
Which language(s) does Dr. Ginna Laport speak?
Which board certifications does Dr. Ginna Laport have?
Other Hematology / Oncology Specialist Near Stanford, CA
(650) 723-9729
Accepting patients
Accepting patients
Accepting patients